Results 151 to 160 of about 22,545,234 (252)

Prospective phase I study of nivolumab to promote graft‐versus‐tumour in relapsed or refractory haematological malignancy post allogeneic haematopoietic stem cell transplantation

open access: yesBritish Journal of Haematology, EarlyView.
Baseline immunophenotype and gene expression predict suitability for salvage nivolumab in patients with relapsed/refractory haematological malignancy. Summary Allogeneic haematopoietic stem cell transplantation (alloHSCT) relies on donor‐derived T cells to mediate the graft‐versus‐tumour (GVT) effect, but relapse may result from impaired immune ...
Trung Q. Ngo   +7 more
wiley   +1 more source

Flow cytometric assessment of T‐cell receptor β‐chain constant region 1/2 skewing as a surrogate marker for clonality in human T‐cell leukaemia virus type‐1–infected cells

open access: yesBritish Journal of Haematology, EarlyView.
Summary Estimating T‐cell clonality within human T‐cell leukaemia virus type 1 (HTLV‐1)–infected cell populations may aid risk assessment and diagnosis of adult T‐cell leukaemia/lymphoma (ATL). However, direct assessment of HTLV‐1 integration‐site clonality requires genetic analyses that are costly and labour‐intensive.
Koji Jimbo   +10 more
wiley   +1 more source

Case Report - Hodgkin's disease in an elderly patient with B-Cell chronic lymphocytic leukemia

open access: yes, 2006
Chronic lymphocytic leukemia (CLL) is the most common type of leukemia worldwide. It is an indolent disease, almost exclusively of B-cell origin. Some CLLs evolve into a more aggressive lymphoid malignancy.
Colak Dilsen, Ozyilkan Ozgur, Akcali Zafer, Bilezikci Banu
core  

Whole‐genome and transcriptome analysis in relapsed/refractory non‐Hodgkin lymphoma: Results from a multicentre precision oncology cohort

open access: yesBritish Journal of Haematology, EarlyView.
Summary Comprehensive genome and transcriptome profiling can inform the diagnosis, prognosis and management of relapsed/refractory (R/R) solid malignancies, yet its integration into clinical care has lagged despite strong biological rationale. We evaluated the clinical utility of whole genome and transcriptome analysis (WGTA) in 65 patients (37 ...
Kathleen Wee   +24 more
wiley   +1 more source

Complex karyotype and non‐BTK driver mutations associated with BTK inhibitor resistance in chronic lymphocytic leukaemia

open access: yesBritish Journal of Haematology, EarlyView.
This graphical abstract illustrates the genetic status in chronic lymphocytic leukaemia (CLL) patients with or without progression on Bruton tyrosine kinase (BTK) inhibitors. It highlights universal clonal evolution, where 100% of progressive disease cases acquired BTK or TP53 mutations.
Kiyomi Mashima   +20 more
wiley   +1 more source

CD20 antigen loss post‐venetoclax/anti‐CD20 therapy in chronic lymphocytic leukaemia: Frequency, characteristics and potential therapeutic implications

open access: yesBritish Journal of Haematology, EarlyView.
Summary Venetoclax plus anti‐CD20 monoclonal antibody (mAb) regimens have revolutionised treatment for chronic lymphocytic leukaemia (CLL); however, CD20 antigen loss is a potential consequence. Given emerging roles for re‐treatment with venetoclax plus anti‐CD20 mAb and CD20‐targeting bispecific antibodies in CLL, we retrospectively assessed the ...
Tamasine Stewart   +15 more
wiley   +1 more source

Long‐read nanopore sequencing: A rapid and highly accurate approach for IGHV gene analysis in chronic lymphocytic leukaemia

open access: yesBritish Journal of Haematology, EarlyView.
Summary The somatic hypermutation (SHM) status of the immunoglobulin heavy variable (IGHV) gene is a key prognostic and predictive biomarker in chronic lymphocytic leukaemia (CLL). Current methods, including Sanger sequencing and short‐read next‐generation sequencing, are accurate but have limitations in scalability and turnaround time.
Teresa del Peso Santos   +6 more
wiley   +1 more source

Leveraging venetoclax‐induced autophagy to enhance AUTAC‐mediated Mcl1 degradation and overcome resistance in acute myeloid leukaemia

open access: yes
British Journal of Haematology, EarlyView.
Ahmed M. Elshazly   +5 more
wiley   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

open access: yesBritish Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu   +6 more
wiley   +1 more source

Outcomes for post‐transplant relapsed acute lymphoblastic leukaemia in the era of novel therapies: A retrospective multicentre UK study

open access: yes
British Journal of Haematology, EarlyView.
Alexandros Rampotas   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy